Clinical Trial: Effectiveness Study of the BioVac Direct Suction Device in Upper Gastrointestinal Bleeding

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: Does the BioVac Direct Suction Device Increase Identification of the Bleeding Source in Upper Gastrointestinal Bleeding: a Randomized Clinical Trial

Brief Summary:

Upper endoscopy is performed for upper gastrointestinal bleeding (bleeding in the esophagus, stomach, or part of the duodenum) to identify and potentially treat the cause of bleeding. However, blood clots often make visualization difficult during endoscopy. The current practice is to try to wash off and suction up these blood clots with the endoscope. However, this is often not successful due to blood clots blocking the suction channel.

A new device has been approved by Health Canada that attaches to the endoscope and helps prevent blockage. It is believed that this device will help doctors suck out blood clots and potentially improve visualization, identification of the cause of bleeding, and possibly health outcomes, although this has never been proven. The purpose of the this clinical trial is to test whether the device works and whether it can help patients with this type of bleeding.


Detailed Summary:

STUDY DESIGN:

This is a randomized double blind clinical trial of the BioVac suction device versus standard endoscopy suction for UGIB. The study will be performed at London Health Sciences Center Victoria Campus and University Campus with an anticipated recruitment period of 2.5 years.

STUDY POPULATION:

All patients over the age of 18 admitted to hospital with a diagnosis of UGIB will be considered for recruitment. Patients already admitted to hospital with another diagnosis who develop UGIB will also be included.

INTERVENTION:

Patients will undergo EGD for UGIB as per standard clinical practice. If the bleeding source is not found within the first 5 minutes (timer starts once EGD passes upper esophageal sphincter) due to blood clots, the patient may benefit from additional suctioning. The patient will be randomized in blocks of 2-6 stratified by site to either the BioVac device or endoscopy suction. Those randomized to the BioVac device will use it to irrigate and suction as much blood as possible until the bleeding source is found or until the endoscopist feels that additional time would not help. Those randomized to endoscopy suction will do the same without the BioVac device. Due to the suctioning power of the study device, a placebo is not possible. Our original intention was to record the endoscopy video to blindly assess the outcome. Unfortunately, this ended up not being possible for technical reasons.


Sponsor: Lawson Health Research Institute

Current Primary Outcome: Identification of cause of bleeding on upper endoscopy [ Time Frame: Once at the time of endoscopy ]

The cause of bleeding will be classified by location (esophagus, stomach, duodenum) and etiology (inflammation, ulcer, mass, varices, angioectasia, Dieulafoy, other).


Original Primary Outcome: Identification of the cause of bleeding [ Time Frame: Once at the time of endoscopy ]

Current Secondary Outcome:

  • Application of any endoscopic therapy [ Time Frame: Once at the time of endoscopy ]
    Treated as a dichotomous outcome (yes, no). Endoscopic therapy include injection, electrocautery, hemostatic clip, variceal banding, or Hemospray
  • Rebleeding [ Time Frame: Measured once 7 days after endoscopy ]
    Rebleeding is defined to have occurred for any of the following: vomiting of fresh blood, shock (systolic blood pressure < 90 mm Hg or heart rate > 110 beats per minute) with melena after stabilization, or a drop in hemoglobin of > 20 g/L within 24 hours after a transfusion to a level > 70 g/L
  • Transfusion requirement [ Time Frame: Measured once 7 days after endoscopy ]
    Total number of units of blood transfused 7 days after endoscopy
  • Length of hospital stay [ Time Frame: Measured once 30 days after endoscopy ]
  • Need for interventional radiology or surgery [ Time Frame: Measured once 30 days after endoscopy ]
  • 30 day mortality [ Time Frame: Measured once 30 days after endoscopy ]
  • Need for repeat EGD within 72 hours [ Time Frame: Measured once 7 days after endoscopy ]
  • Procedure duration [ Time Frame: Once at the time of endoscopy video review ]


Original Secondary Outcome:

  • Visualization score [ Time Frame: Once at the time of endoscopy ]

    A visualization score will be used as follows:

    Score of 0 - 4 per location (0 = <25%, 1 = 25-50%, 2 = 51-75%, 3 = 76 - 95%, 4 = >95%) Scored for the following locations: esophagus, fundus, body, antrum, duodenal bulb, second part of the duodenum

  • Application of any endoscopic therapy [ Time Frame: Once at the time of endoscopy ]
    Treated as a dichotomous outcome (yes, no). Endoscopic therapy include injection, electrocautery, hemostatic clip, variceal banding, or Hemospray
  • Rebleeding [ Time Frame: Measured once at 7 days after endoscopy ]
    Rebleeding is defined to have occurred for any of the following: vomiting of fresh blood, shock (systolic blood pressure < 90 mm Hg or heart rate > 110 beats per minute) with melena after stabilization, or a drop in hemoglobin of > 20 g/L within 24 hours after a transfusion to a level > 70 g/L
  • Transfusion requirement [ Time Frame: Measured once at 7 days after endoscopy ]
    Total number of units of blood transfused 7 days after endoscopy
  • Length of hospital stay [ Time Frame: Measured once at 30 days after endoscopy ]
  • Need for repeat EGD within 7 days [ Time Frame: Measured once at 7 days after endoscopy ]
  • Need for interventional radiology, surgery, or TIPS [ Time Frame: Measured once at 30 days after endoscopy ]
  • 30 day mortality [ Time Frame: Measured once at 30 days after endoscopy ]


Information By: Lawson Health Research Institute

Dates:
Date Received: May 22, 2014
Date Started: April 2015
Date Completion:
Last Updated: November 14, 2016
Last Verified: November 2016